哈药股份：哈药集团累计质押股份约8.44亿股

Group 1 - The core point of the article is that Harbin Pharmaceutical Group Co., Ltd. (哈药股份) announced the status of its major shareholder's shareholding and the composition of its revenue for the year 2024 [1] Group 2 - Harbin Pharmaceutical Group Co., Ltd. holds approximately 1.173 billion shares of Harbin Pharmaceutical, accounting for 46.58% of the total share capital [1] - After the completion of the recent pledge release, Harbin Pharmaceutical Group has pledged a total of approximately 844 million shares, which is 71.96% of its holdings and 33.52% of the total share capital [1] - For the year 2024, the revenue composition of Harbin Pharmaceutical is as follows: 36.87% from wholesale medical customers, 16.14% from pharmaceutical industry - health products, 15.87% from chemical preparations, 13.99% from wholesale commercial customers, and 10.46% from pharmaceutical commercial - retail [1] - As of the report, the market capitalization of Harbin Pharmaceutical is 9.1 billion yuan [1]